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Abstract
Surfactant protein B (SP-B, gene name: sftpb) is essential for normal lung function. It
reduces alveoli surface tension, thereby preventing the lung from collapse. A single
nucleotide polymorphism (SP-B 1580 C/T) is associated with several lung diseases and
altered N-linked glycosylation site at Asn129 of SP-B. This change, present in the human
population, has been associated with negative effects on SP-B precursor (proSP-B)
processing and function. In this study, hSP-B humanized transgenic mice were generated
without mouse SP-B background. Four founding lines, showing only the hSP-B gene,
were selected via PCR-based DNA analysis. Genomic sequencing of these mice revealed
which allele variant (hSP-B-C/T) they carried. Western blot analysis of BALF samples
revealed these hTG mice expressed hSP-B protein in levels significant for survival and
comparable to that of a healthy human lung. Characterization of the two hSP-B allele
variant hTG strains revealed significant differences in their relative alveolar size and total
lipid concentration.
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Executive Summary

Surfactant protein B (SP-B, genus name: sftpb) is a vital component of a healthy and
normally functioning lung. It coats the surface of alveoli and prevents them from
collapsing by lowering surface tension. Alveoli, hollow sacs found in the lung, are the
site of oxygen and carbon dioxide exchange in the body. Modification of the gene that
codes for this protein can lead to its dysfunction and cause serious, even fatal, lung
complications. This paper looks to analyze one such modification. SP-B gene encodes a
protein that is 381 amino acids (building blocks of protein) in length. A single nucleotide
change (from ‘T’ to ‘C’) in the DNA changes one of these amino-acids from a Threonine
to an Isoleucine. This small change has a drastic effect on how the protein folds together
and subsequently how it performs. The two forms (alleles) of this gene are labeled Callele (SP-B-C), which contains the modification, and wild type (normal) T-allele variant
(SP-B-T) which does not. This change, which has been associated with decreased lung
function, is common in the human population and represents an important avenue of
research.
To study the effect this genetic modification has on physiological function and structure,
humanized transgenic mice (hTG) were created. hTG SP-B mice express human SP-B
(hSP-B) but not mouse SP-B (mSP-B). To generate these mice, the human SP-B gene
was inserted into mouse oocytes. These mice, which now contain both the mouse SP-B
gene and human gene, were bred with ‘knockout’ mice (KO) that did not express either
form of the gene. From the resulting offspring, mice that expressed only the human gene,
and not the mouse SP-B gene, were selected for testing in this experiment. This selection
was accomplished by taking tail samples and testing the DNA for mice that were human
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SP-B conditional. This test confirmed that the human gene had successfully been inserted
into the (now humanized transgenic) mice and was being expressed at levels sufficient
for survival. Four ‘Founder’ strains had been selected and were given labels: 2004, 2007,
2012, and 2059. Next, the DNA from each of these four founder strains was sequenced to
see if they contained the SP-B gene modification. Of the four strains, only one (2012)
was determined to contain the C-allele while the rest (2004, 2007, 2012) contained the
T-allele.
The goal of this paper was to characterize the hSP-B gene successfully established in
these humanized transgenic mice and to compare the two allele variants (C/T) to samples
taken from a healthy human. The following factors were tested: relative size of alveoli,
SP-B expression levels, and total lipid concentration. Alveolar size was tested by taking
lung samples from each of the four founder strains and viewing them under a microscope.
Relative size was then determined by superimposing these images over a grid and
counting the number of intersections (‘hits’) that each alveolus contained. 100 alveoli
from each founder strain were tested and used to calculate average size. Results indicated
that mice containing the C-allele (hSP-B-C) had significantly larger alveoli compared to
those containing the T-allele (hSP-B-T). Protein expression levels and lipid concentration
were determined by testing broncho-alveolar lavage fluid (BALF). BALF is obtained by
injecting a sterilized solution into the lung and withdrawing it back (now containing lung
material) for use in further testing. The level of hSP-B expression in the hTG mice was
determined using western blot analysis. In this method, proteins are separated by their
molecular weight. Since the molecular weight of human SP-B is known, western blot
analysis allowed not only for confirmation that hSP-B was being expressed by the mice
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but also to what extent. Results of this testing indicated that the level of hSP-B protein
expression in the lung of these transgenic mice is comparable with that in the human
lung. Lipid concentration was determined by testing the degree to which these samples
could absorb UV light. These results indicated that the level of lipid concentration was
significantly higher in the BALF taken from a C-allele mouse compared to that of the Tallele variant and also to that found in a healthy human. The T-allele showed comparable
lipid concentration to that of the human sample.
In summary, humanized transgenic mice were generated that carried human SP-B
C-allele or T-allele. hSP-B expression levels were sufficient for survival and were
comparable with that in the human lung. Characterization of these hSP-B two allele
variants reveled significant differences in their relative alveolar size and total lipid
concentration.
These differences should help drive the future research needed to ascertain the specific
nature of the C-allele’s negative effect on the host’s ability to fight respiratory diseases.
Since this mutation is common in the human population, the ability to identify patients
containing this C-allele variant could lead to modified treatment and an increased success
rate in fighting their respiratory disease.

7

Acknowledgments
I wish to thank Dr. Guirong Wang for his all-encompassing mentorship over the past two
years. His enduring belief in my work and in my future have meant more than he will
ever know. I wish also to thank Dr. Osama Abdel Razek for his patience, expertise and
friendship. His continued support of me and for this project were invaluable to its
completion.

8

Introduction
Surfactant protein B (SP-B gene name: sftpb) is essential for effective pulmonary
respiration and physiological function. Pulmonary surfactant, a lipid and protein complex
synthesized by alveolar type II cells, lines alveoli at the gas-liquid interface and reduces
surface tension, thereby preventing the lung from collapse. Surface tension arises as
water molecules are more strongly attracted to one another than to air molecules causing
an inwardly directed force that tends to reduce surface area [1]. During low lung volumes
(expiration), surfactant is squeezed out of the surface of the alveoli and forms micelles.
Upon inspiration, this film is spread over the surface of the alveoli reducing surface
tension and maintaining the structural integrity of the lung. Surfactant-associated protein
is made up of four primary functional components: surfactant protein A (SP-A),
surfactant protein B (SP-B), surfactant protein C (SP-C), and surfactant protein D (SP-D).
Surfactant proteins A and D are important in immunity and host defense while SP-B is a
vital structural component of the surfactant. SP-B loss of function causes surfactant death
and subsequently alveolar collapse and decreased lung function. Human SP-B (hSP-B)
genetic variation has been associated with several fatal respiratory diseases, such as
congenital alveolar proteinosis [2-4], and SP-B-deficient mice exhibit pulmonary
dysfunction and die shortly after birth [5]. Two variants will be examined in this paper: T
allele and C allele. A single nucleotide polymorphism (SN, rs1130866) SP-B 1580 C/T
alters N-linked glycosylation of Asn129, which is present in the C allele but absent in the
T allele [6]. This alteration in N-linked glycosylation pattern may influence SP-B
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precursor processing and function. hSP-B precursor contains three Saposin-like protein
(SAPLIP) domains, SP-BN, SP-BM, and SP-BC. N-Linked glycosylation occurs in the SPBN domain. For this study, humanized transgenic mice were successfully generated that
contain either the C or T allele of the human SP-B gene without mouse SP-B background.
Transgenic mice showed comparable hSP-B expression with that in the human lung and
also showed normal phenotypes as wild type (WT) mice. These results indicate that
hSP-B is functional in the transgenic mice. The goal of this study was to characterize this
humanized sftpb transgenic mouse line.

Materials and Methods
Mice and animal husbandry
Wild type mice used for this study were purchased from the Jackson Laboratory (Bar
Harbor, ME). They were then maintained in the animal core facility of SUNY Upstate
Medical University (SUNY UMU) throughout the duration of the study. hTG SP-B mice
generated for this study were conditional hSP-B transgenic mice (contained the
background of SP-B KO mice). All mice used for this study were handled by the
protocols approved by the Institutional Animal Care and Use Committee of SUNY
UMU.

Constructs for generation of TG SP-B and conditional TG SP-B mice

To generate hSP-B mice, the cDNA of human sftpb had to first be cloned into a suitable
vector and initiated by a human promoter. This was accomplished by cloning the cDNA
into a basic 3.7-hSP-C/SV40 plasmid. A 5.4 kb DNA fragment of this vector was then
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excised from the recombinant plasmids and microinjected into fertilized FVB/N oocytes
from wild type mice.

Generation of hTG SP-B Mice
The generation of an hTG SP-B strain began by mating mice which carried both the
mouse and human genes (hSP-B+/-, mSP-B+/+) with SP-B KO mice which expressed
neither gene (hSP-B-/-, mSP-B-/-). This yielded hTG SP-B F1 mice (hSP-B+/-, mSPB+/-). This strain was then mated with SP-B KO mice to block the mouse SP-B gene.
KO mice (conditional transgenic) could not express mSP-B due to a neomycin resistant
gene that was inserted into exon 4 of their SP-B gene. Finally, homozygous hTG hSP-B
mice could be obtained by the self breeding of F2 mice from the same founder. hTG
SP-B mice were therefore defined as being human SP-B positive and mouse SP-B
negative (hSP-B +/+, mSP-B-/-)

Genotype analysis of the hTG SP-B mice
Genotyping was required to correctly identify the hTG SP-B mice. 0.5-1.0cm tail
samples were obtained from new born pups after being weaned from their parents using
a Qiagen DNeasy kit (Qiangen, Valencia, CA). The quality of the DNA was analyzed
using Nano Drop. Two Polymerase Chain Reactions (PCR) amplifications were
performed using the same DNA sample as the template: primer pair 1458/189 (which
was used to screen hSP-B) and primer pair 75/76 (which was used to amplify mSP-B).
Conditions for the running of the PCR were as follows: 95°C for 2 minutes, then 95°C
for 40s, 58°C for 40s, and 68°C for 40s.This cycle was run 35 times with the final
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extension step being performed for 7 minutes at 68°C. Products of this PCR were then
examined utilizing 2% agarose gel electrophoresis and an EB stain solution. Only
samples that showed the hSP-B band exclusively were labeled as human SP-B positive
and mouse SP-B negative. To identify the polymorphism allele at site +1580, primer
pair 1458/1401 was used to amplify the whole fragment of hSP-B gene from the positive
DNA samples by High Fidelity PCR kit (Roche). The PCR for this sample was varied
from the reaction prior. Initial denaturation was run for 2 minutes at 94°C followed by
10 cycles of the following conditions: 94°C 30s, 58°C 30s and 72°C 2 minutes. This was
followed by two cycles of: 94°C 30s, 58°C 30s and 72°C 3 minutes. The final step was
extension at 72°C for 7 minutes. The PCR products were sequenced by the Core Facility
of SUNY Upstate Medical University.

Western blot analysis of surfactant proteins from mouse BALF

Western blot analysis was performed on the broncho-alveolar lavage fluid (BALF) of
positive mice to identify expression levels of human SP-B protein in hTG SP-B mice.
Samples were taken from mice (8-12 weeks) and lavaged with 0.5 mL of autoclaved
PBS solution. Total protein concentration of the BALF was measured by BCA micro
assay kit (Thermo). 10 µg of total protein was loaded on a 12% non-reducing SDSPAGE gel. 10 µg of human BALF was also loaded onto the gel for use as a positive
control. Electrophoresis was run on the samples at 60V for 30 minutes followed by
110V for 1 hour. The human SP-B protein was identified by anti-pig SP-B antibodies as
well as two others, labeled as Antibody 1 and Antibody 2, which were created in the lab
for use on this protein. Antibodies were used at 1:5000 and 1:10000 dilutions.
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Histological and cellular analysis

To observe the histological structure and determination of relative alveolar size, lungs
from positive mice (C and T allele) were fixed by 10% formalin solution at about 25 cm
of water pressure, and then processed into paraffin blocks. Blocks were cut into pieces
with thickness of roughly 5 µm. Sections were stained by hematoxylin and eosin kit
while others were stained with ABC kit (Vector Laboratories, Burlingame, CA).

Determination of Relative Alveolar Size using Delesse Method
Samples prepared for histological and cellular analysis placed on microscope slides and
viewed using a Nikon Eclipse TE2000-U microscope at 20x magnification. To conduct
the Delesse Method of determining relative alveolar size, the images were superimposed
on a grid. From this grid, the number of intersections (‘hits’) that each alveolus contained
was counted. 100 alveoli were used for each founder strain and used to calculate average
size.

Determination of Lipid Concentration from BALF
BALF samples from each founder variant (CT) and from a healthy human had to first be
diluted to 1:10 adequate detection and determination of lipid concentration (mg/mL).
For each sample, 15 µL of BALF was added to 135 µL of PBS buffer and the resulting
solution was loaded into a Multiskan Ascent V1.24 to determine absorbance. To
determine lipid concentration, absorbance of the samples were compared to the known
absorbance of albumin at a preset concentration. Lipid concentration of each variant
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strain of hTG mice (hSP-B-C/T) were compared to one another and also to that of the
sample from a healthy human.
* All experiments were repeated at least three times. Western blot bands were quantified
by Quantity One (version 4.6.1). Statistical analysis was performed by Sigma Stat version
3.5 software. Significant difference in statistics among groups was considered when
p < 0.05 by t-test or ANOVA

Results

1. Generation of SP-B-T and SP-B-C mice and transgene transmission in the
offspring
The generation of human SP-B transgenic mice began by cloning the cDNA of human
sftpb into a basic 3.7-hSP-C/SV40 vector and driven by the human sftpb promoter. A
5.4 kb DNA fragment was then excised from the recombinant plasmid and microinjected
into fertilized FVB/N oocytes from wild type mice. Four founder lines of hTG SP-B mice
were generated and identified by PCR amplification of DNA fragment of SP-B: 2004,
2007, 2012, and 2059. Endogenous mouse SP-B background was eliminated by the use of
conditional human SP-B transgenic mice, while expression of the mouse SP-B gene was
shut down by the insertion of a Neomycin resistant gene into SP-B exon 4. These mice
were named as KO (hSP-B -/mSP-B -). Next, an F1 generation of hTG mice (hSP-B
+/mSP-B +) was generated by the mating of these conditional human SP-B transgenic
mice with hSP-B positive transgenic founders. Positive mice in the F1 generation were
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then bred with KO mice to generate a line of F2 positive mice (hSP-B+/mSP-B-).
Summary of this breeding process can be seen below in Figure 1:
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Genotype analysis was then conducted via PCR to amplify fragments of both the mSP-B
and hSP-B. hSP-B was amplified with primer pair 1458/1401 locating on the SP-C
promoter and the 3’ end of SP-B cDNA respectively. Amplification of this gene yields a
PCR product of 577bp. Conversely, mSP-B was amplified with primers 75 and 76 which
locate the 3’ end of intron 3 and the 5’ end of intron 4 respectively. Amplification of this
gene leaves a product that is 279 bp. Humanized SP-B mice showing only the hSP-B
band (577 bp) were were selected out of this F2 generation and used for this study
(Figure 2).
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Genetic sequencing of these mice (labeled F3) was conducted to detect the presence of a
single-nucleotide polymorphism (SNP) in SP-B gene exon 4 position 1580 (Figure 3A).
The T/C allele variation changes amino acid 131, causing a change from threonine to
isoleucine (Thr131-Ile). This change eliminates an N-linked glycosylation site, Asn129Gln-Thr131, present in the C allele (hSP-B-C) but not the wild type T allele (hSP-B-T). It
has been reported that the C allele is associated with increased risk of acute respiratory
distress syndrome (ARDS) and respiratory failure in adults [7-8]. Samples were sent from
each founder strain to the University’s Core facility for sequencing analysis. The data
reported that three of the 4 founders (2004, 2007, 2059) carried the T allele while founder
2012 carried the lone C allele (Figure 3B).
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2.

Comparison of alveolar size in hSP-B-C and hSP-B-T transgenic mice.

To compare the relative size of alveoli between humanized transgenic mice, lung tissue
was harvested from each of the four founder strain (8-12 weeks). Samples were fixed by
10% formalin solution at about 25 cm of water pressure and then processed into paraffin
blocks. From these blocks, 5 µm thick sections were cut, placed on microscope slides,
and stained by hematoxylin and eosin staining kits. Relative size of alveoli was
estimated using the Delesse Method in which microscopic images of alveoli cells were
superimposed on a grid. From this grid, the number of line intersections (hits) within
each alveoli was counted and averaged for each founder strain thus estimating relative
differences in total size the alveoli themselves. All images were taken when viewed at
20x magnification on a Nikon Eclipse TE2000-U microscope and overlain on the same
grid. For each founder, 50 alveoli from two separate mice were sampled and used for
calculation. The results (Figure 4) indicate a sizable difference in the relative size of
alveoli between hSP-B-C and hSP-B-T transgenic mice.
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3. Western Blot Analysis
SP-B gene codes a 381 amino acid long precursor (pro-SP-B) that has a molecular mass
of 42 kDa. This proSP-B undergoes extensive post-translational processing (See Figure
5) to yield mature SP-B (region comprising 201-279) which has a molecular mass of 8
kDa and is found in broncho-alveolar lavage material.
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Processing of proSP-B includes cleavage of signal peptides, glycosylation of C-terminus,
and cleavage of N and C terminal propeptides [9]. Pepsinogen C is an aspartyl protease
that has been identified as an important player in this post-translational modification by
cleaving proSP-B at Met302 and Ser197 [10]. Western Blot analysis of BAL fluid was
conducted to determine the extent of hSP-B gene expression in each of the four strains of
hTG mice. BAL fluid and lung tissue were prepared from each founder and compared to
the BAL fluid from a healthy adult which was used as a positive control. Human SP-B
gene was identified by used of 3 antibodies: Alpha-pig antibody, Antibody 1, and
Antibody 2. Alpha-pig is a commercially purchased identification antibody that detects
mature SP-B. Non-reducing gel for was used for these samples as it allowed for better
detection. As a result, mature SP-B presented as a dimer and showed a band at 16 kDa
instead of its actual molecular mass of 8 kDa. Antibodies 1 and 2 are used to detect
proSP-B and fragments of partially processed SP-B (42, 28 kDa). Our results indicate
that human SP-B was successfully integrated and expressed in hTG mice at levels
sufficient for survival (see figure 6-8). Bands of known molecular mass, corresponding to
regions in proSP-B and mature SP-B, were seen in both human BAL fluid samples as
well as in each hTG mouse strain. Quantification of hSP-B expression was then
conducted using Quantity One software (version 4.6.1). Results of this analysis indicate
that hSP-B was expressed in both variants (C/T) of hTG mice in comparable levels to that
found in human BAL fluid (see Figure 9).
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Figures 6-8 Western Blot Analysis
hSP-B expression in hTG mice was confirmed through western blot testing of BALF
samples taken from each of the four Founder strains (2004, 2007, 2012, 2059). 20µg of
total protein from F2 mice of 4 different founders was subjected to 12% SDS-PAGE
under non-reducing condition. A human BALF was used as a positive control Gels were
subjected to one of four different antibodies used for identification. Figures 6 shows both
sham and infected (pneumonia) mouse BALF detected with AB1 which identifies proSPB (42 kDa). Figure 7 shows the same samples when detected by AB2 which also identifies
portions of proSP-B (28 kDa). Figure 8 shows the dimer (a 16kD band) of mature hSP-B
after being detected with Alpha-pig antibody These results indicate all four of founders
can express sufficient hSP-B protein for survival.
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4. Lipid Concentration
Total lipid concentration was determined from BAL fluid samples from both variant
strains of hTG mice (hSP-B-C/T) and compared to that of BAL fluid taken from a
healthy human. Samples were diluted to 1:10 by PBS and run through a Multiskan
Ascent V1.24. Samples were compared to albumin which served as the calibration blank.
Results (Figure 11) showed that the T variant (2007) showed comparable lipid
concentration levels (0.0708 ± 0.00203 mg/ml) to that of the human sample (0.054
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mg/ml) while the C variant (2012) showed significantly higher lipid concentration
(0.13825 ± 0.00256 mg/ml).

Discussion

Surfactant Protein B (SP-B), a lipid protein complex, plays a critical role in the lung’s
physiological function and structural integrity by reducing alveolar surface tension. A
single polymorphism SP-B (1580 C/T) causes the change of amino acid 131 from
threonine to isoleucine (Thr131-Ile). This change alters N-linked glycosylation which may
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in turn alter SP-B precursor (proSP-B) post-translational processing and function. This
glycosylation, which occurs at Asn129, is present in the C-allele variant (hSP-B-C) but is
absent in the T-allele variant (hSP-B-T). It has been reported that the C-allele is
associated with increased risk of ARDS and other respiratory conditions in adults.
Generation of an hTG mouse line, containing hSP-B without background mSP-B, began
by the cloning of human sftpb cDNA into a suitable vector and initiated by a human
promoter. A DNA fragment of the recombinant plasmid was microinjected into fertilized
WT mouse oocytes. These mice, now containing both the mouse and human SP-B gene
were bred with conditional transgenic mice (KO) to remove the mSP-B background
(Figure 1). SP-B fragment in the KO mice could not be expressed due to a neomycin
resistance gene that was inserted into their SP-B gene. Mouse tail samples were collected
from these transgenic mice and genotyped along with positive and negative controls by
amplification of both human SP-B and mouse SP-B fragments via PCR (Figure 2). Mice
that showed the hSP-B gene without mSP-B background (hSP-B+/mSP-B-) were selected
and used in this study. Of this group, four Founder strains were selected (2004, 2007,
2012, 2059) and subjected to genetic sequencing. This sequencing was performed to
identify the C/T allele variant type of each Founder strain. Only the 2012 strain showed
the C-allele while the other three strains exhibited the T-allele (Figure 3). After
identifying the gene in the four Founder strains, attention shifted to characterization of
hSP-B in these hTG mice. Comparison of alveolar size was conducted via the Delesse
Method. Results (Figure 4) indicated that the 2012 C-allele variants have significantly
larger alveoli (26.98±1.227 hits/alveoli) than any of the T-allele variant strains. Western
Blot Analysis was performed to identify expression of the hSP-B in the BALF of hTG
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Founder strains. SP-B gene codes a 381 amino-acid precursor that undergoes extensive
post-translational modification (Figure 5). Three antibodies (AB1, AB2, Alpha-pig) were
used for detection of both pro-SP-B and mature SP-B fragments. Results show that hSPB was expressed in all of the founder strains at levels sufficient for survival (Figures 6-9).
To compare SP-B expression levels with those found in humans, quantification of the
western blot bands was performed. Scans of the western blot gels were subjected to
analysis by Quantity One software. Results of the quantification (Figure 10) indicate that
hSP-B was expressed in the four Founder hTG mice in comparable levels to that of the
human sample (positive control). BALF samples from each variant type (C/T) were then
subjected to lipid concentration testing and compared BALF from a healthy human.
Albumin was used as the calibration blank. Results indicate that the 2012 C-allele variant
exhibited significantly higher lipid concentration than either the T-allele variant or human
sample. The T-allele variant and the human sample exhibited similar concentration levels
(Figure 11).

Conclusion
Humanized sftpb transgenic founder lines carrying the human SP-B C allele or T allele
were generated and showed normal phenotypes as WT mice. The level of hSP-B protein
expression in the lungs of these transgenic mice is comparable with that in the human
lung indicating hSP-B is functional within these founder lines. Characterization of the
two hSP-B allele hTG strains revealed significant differences in their relative alveolar
size and total lipid concentration. These differences should help drive the future research
needed to ascertain the specific nature of the C-allele’s negative effect on the host’s

25
ability to fight respiratory diseases. Since this mutation is common in the human
population, the ability to identify patients containing this C-allele variant could lead to
modified treatment and an increased success rate in fighting their respiratory disease.
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